An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy

An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy

The HER2 monoclonal antibody, Trastuzumab, is the current standard treatment for HER2+ cancers but resistance to therapy occurs. Here, the authors show that activation of the PKR/eIF2α-P pathway exhibits anti-tumor effects in HER2+ cancer and is required for the response to Trastuzumab.

Guardado en:
Detalles Bibliográficos
Autores principales: Cedric Darini, Nour Ghaddar, Catherine Chabot, Gloria Assaker, Siham Sabri, Shuo Wang, Jothilatha Krishnamoorthy, Marguerite Buchanan, Adriana Aguilar-Mahecha, Bassam Abdulkarim, Jean Deschenes, Jose Torres, Josie Ursini-Siegel, Mark Basik, Antonis E. Koromilas
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/7ecf6c59b1264893ab9910b75de10e72
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/7ecf6c59b1264893ab9910b75de10e72

Ejemplares similares